C₂N is a specialty diagnostics company providing exceptional laboratory services and products in the field of brain health. C₂N’s high-resolution mass spectrometry-based biomarker products and services are used for: clinical decision-making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiological studies to improve global public health.

C₂N’s Precivity™ tests are innovative new blood test intended for use in patients with cognitive impairment. These tests aim to help healthcare providers determine the presence or absence of amyloid plaques in the brain, a hallmark sign of Alzheimer’s disease, and aid in medical management and treatment decisions.

The PrecivityAD2™/PrecivityAD® blood tests are intended for use in patients aged 55 and older with signs or symptoms of mild cognitive impairment or dementia who are undergoing evaluation of Alzheimer’s disease or dementia.

The Precivity-ApoE™ blood test is indicated for use in adult patients for whom knowledge of apolipoprotein E2,E3,E4 allele status may be informative for medical management and treatment decisions.

 Only a healthcare provider can order the Precivity™ tests.

The test is available in 49 states and the District of Columbia; the exceptions are the State of New York, which requires and individual state process for CLIA labs, and Puerto Rico. C₂N is working toward obtaining the requisite certification that will permit the PrecivityAD® test to be available in New York in the near future. Please periodically refer back to this website or contact C₂N at 1.877.C2N.DIAG (226.3424) for a status update on test availability in New York.